Literature DB >> 32289177

A glimpse at growth hormone-releasing hormone cosmos.

Nektarios Barabutis1.   

Abstract

Growth hormone-releasing hormone is a hypothalamic neuropeptide, which regulates the secretion of growth hormone by the anterior pituitary gland. Recent evidence suggest that it exerts growth factor activities in a diverse variety of in vivo and in vitro experimental malignancies, which are counteracted by growth hormone-releasing hormone antagonists. Those peptides support lung endothelial barrier integrity by suppressing major inflammatory pathways and by inducing the endothelial defender P53. The present effort provides information regarding the effects of growth hormone-releasing hormone in the regulation of P53 and the unfolded protein response. Furthermore, it suggests the possible application of growth hormone-releasing hormone antagonists towards the management of acute lung injury, including the lethal acute respiratory distress syndrome.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  P53; endocrinology; endothelium; growth factors; inflammation

Year:  2020        PMID: 32289177      PMCID: PMC7426234          DOI: 10.1111/1440-1681.13324

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  45 in total

1.  Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264.7 cells by suppression of NF-κB and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation.

Authors:  Song-Yi Kim; Ji-Sun Hwang; Inn-Oc Han
Journal:  Eur J Pharmacol       Date:  2013-09-18       Impact factor: 4.432

2.  GHRH antagonists support lung endothelial barrier function.

Authors:  Mohammad A Uddin; Mohammad S Akhter; Sitanshu S Singh; Khadeja-Tul Kubra; Andrew V Schally; Seetharama Jois; Nektarios Barabutis
Journal:  Tissue Barriers       Date:  2019-10-03

3.  P53: The endothelium defender.

Authors:  Mohammad Afaz Uddin; Nektarios Barabutis
Journal:  J Cell Biochem       Date:  2019-02-28       Impact factor: 4.429

Review 4.  Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists.

Authors:  Andrew V Schally; Xianyang Zhang; Renzhi Cai; Joshua M Hare; Riccarda Granata; Manuela Bartoli
Journal:  Endocrinology       Date:  2019-07-01       Impact factor: 4.736

Review 5.  Growth hormone-releasing hormone: not only a neurohormone.

Authors:  Hippokratis Kiaris; Ioulia Chatzistamou; Athanasios G Papavassiliou; Andrew V Schally
Journal:  Trends Endocrinol Metab       Date:  2011-04-27       Impact factor: 12.015

Review 6.  Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation.

Authors:  Stefan R Bornstein; Karin Voit-Bak; Peter Rosenthal; Sergey Tselmin; Ulrich Julius; Ulrike Schatz; Bernhard O Boehm; Sandrine Thuret; Gerd Kempermann; Heinz Reichmann; George P Chrousos; Julio Licinio; Ma-Li Wong; Andrew V Schally; Richard Straube
Journal:  Mol Psychiatry       Date:  2019-10-08       Impact factor: 15.992

7.  Regulation of lung endothelial permeability by NEK kinases.

Authors:  Nektarios Barabutis
Journal:  IUBMB Life       Date:  2020-02-11       Impact factor: 3.885

8.  The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.

Authors:  Marta Annunziata; Cristina Grande; Francesca Scarlatti; Francesco Deltetto; Elena Delpiano; Marco Camanni; Ezio Ghigo; Riccarda Granata
Journal:  Fertil Steril       Date:  2009-06-12       Impact factor: 7.329

9.  Introduction of Dr. Andrew V Schally.

Authors:  Arturo Mendoza-Valdés
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

10.  Wild-type p53 enhances endothelial barrier function by mediating RAC1 signalling and RhoA inhibition.

Authors:  Nektarios Barabutis; Christiana Dimitropoulou; Betsy Gregory; John D Catravas
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

View more
  5 in total

1.  Unfolded protein response in endothelial injury.

Authors:  Nektarios Barabutis
Journal:  Cell Cycle       Date:  2022-05-26       Impact factor: 5.173

2.  Protective effects of GHRH antagonists against hydrogen peroxide-induced lung endothelial barrier disruption.

Authors:  Mohammad S Akhter; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Endocrine       Date:  2022-10-20       Impact factor: 3.925

3.  P53 deficiency potentiates LPS-Induced acute lung injury in vivo.

Authors:  Mohammad A Uddin; Mohammad S Akhter; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  Curr Res Physiol       Date:  2020-07-09

4.  Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs.

Authors:  Mohammad S Akhter; Mohammad A Uddin; Andrew V Schally; Khadeja-Tul Kubra; Nektarios Barabutis
Journal:  J Cell Commun Signal       Date:  2020-11-13       Impact factor: 5.782

Review 5.  P53 in the impaired lungs.

Authors:  Mohammad A Uddin; Nektarios Barabutis
Journal:  DNA Repair (Amst)       Date:  2020-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.